Skip to main content

Drug Interactions between Accolate and etravirine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

zafirlukast etravirine

Applies to: Accolate (zafirlukast) and etravirine

MONITOR: Coadministration of etravirine with a drug that is both a substrate as well as inhibitor of CYP450 2C19 and/or 2C9 may result in increased plasma concentrations of both drugs. Etravirine itself is also a substrate and inhibitor of CYP450 2C19 and 2C9. Theoretically, metabolism of etravirine and the coadministered drug may be mutually inhibited when used in combination. In 18 study subjects administered etravirine with the CYP450 2C19 inhibitor omeprazole (40 mg once a day), etravirine peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 17% and 41%, respectively. The effect of etravirine on omeprazole pharmacokinetics was not reported.

MANAGEMENT: Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with a CYP450 2C19 or 2C9 inhibitor. In addition, dosage adjustments may be required for the coadministered drug if it is also a substrate of CYP450 2C19 or 2C9.

References

  1. (2008) "Product Information. Intelence (etravirine)." Ortho Biotech Inc

Switch to consumer interaction data

Drug and food interactions

Moderate

zafirlukast food

Applies to: Accolate (zafirlukast)

ADJUST DOSING INTERVAL: Food may reduce the oral absorption and bioavailability of zafirlukast. In two separate studies, one using a high-fat and the other a high-protein meal, administration of zafirlukast with food reduced the mean bioavailability by approximately 40%.

MANAGEMENT: To ensure maximal oral absorption, zafirlukast should be administered at least 1 hour before or 2 hours after meals.

References

  1. (2001) "Product Information. Accolate (zafirlukast)." Astra-Zeneca Pharmaceuticals

Switch to consumer interaction data

Moderate

etravirine food

Applies to: etravirine

ADJUST DOSING INTERVAL: Coadministration with food increases the oral bioavailability of etravirine. The mechanism is unknown. Compared to administration following a meal, the systemic exposure (AUC) to etravirine was decreased by about 50% when the drug was administered under fasting conditions. The types of meal studied (ranging from 345 kilocalories containing 17 grams fat to 1160 kilocalories containing 70 grams fat) did not appear to make a difference with respect to impact on etravirine bioavailability.

MANAGEMENT: Etravirine should always be administered following a meal.

References

  1. (2008) "Product Information. Intelence (etravirine)." Ortho Biotech Inc

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer